What is Rip Road?
Rip Road, Inc. operates at the intersection of patient empowerment and pharmaceutical efficacy, providing specialized software solutions that facilitate the collection and analysis of PGHD. By enabling patients to actively participate in their therapy management, the company bridges the information gap between clinical outcomes and real-world medication performance. Their platform is engineered to deliver actionable evidence, allowing patients to engage in more informed dialogues with their healthcare providers. With an ISO 13485:2016 certification, Rip Road maintains a rigorous quality management standard, positioning itself as a reliable partner for pharmaceutical brands seeking to enhance patient adherence and therapeutic success through data-driven insights.
How much funding has Rip Road raised?
Rip Road has raised a total of $491K across 2 funding rounds:
Debt
$150K
Debt
$341K
Debt (2020): $150K with participation from PPP
Debt (2021): $341K led by PPP
Key Investors in Rip Road
PPP
Public-Private Partnership
What's next for Rip Road?
With this substantial capital backing, Rip Road is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its software capabilities and the deepening of its integration with existing healthcare delivery systems. The company is expected to leverage these resources to enhance its data analytics engine, thereby providing pharmaceutical partners with more granular insights into patient behavior and medication effectiveness. As the digital health landscape continues to prioritize patient-centric models, Rip Road's focus on evidence-based therapy management will likely serve as a key differentiator, driving long-term value for stakeholders and improving clinical outcomes on a broader scale.
See full Rip Road company page
